OP0079 OMICRON VARIANT INFECTION IN INFLAMMATORY RHEUMATOLOGICAL CONDITIONS - OUTCOMES FROM A COVID-19 NAIVE POPULATION IN AOTEAROA NEW ZEALAND

Background Due to geographic isolation and border controls, Aotearoa New Zealand attained high levels of population coronavirus disease-19 (COVID-19) vaccination before widespread community transmission Omicron variant COVID-19 in early 2022. This provides a unique opportunity examine outcomes people with rheumatic diseases immunologically naive COVID-19. Objectives study aims describe the infection Zealand. Methods We conducted an observational inflammatory disease from centers between 1 February 30 April Data were collected via Global Rheumatology Alliance Registry, including demographic characteristics outcomes. Multivariable logistic regression was used explore associations clinical factors hospitalisation death. Results A total 1599 cases included, 98% three hospitals that systematically identified all patients rheumatology clinics who had infection. At time infection, 1513 (94.6%) received at least two vaccinations. Hospitalisation occurred for 104 (6.5%) cases, 10 (0.6%) died. lower frequency seen vaccinations (5.9%), compared unvaccinated (20.6%) or single vaccine dose (10.7%). In multivariable adjusted models, gout (OR 2.2 95% CI 1.02, 4.77) connective tissue (CTD) 2.78 1.61, 4.80) increased risk combined outcome death, arthritis. Glucocorticoid rituximab use associated 3 6 times higher odds hospitalization and/or All died more co-morbidities known poor over 60 years old. Conclusion this cohort rates, severe infrequent. The rate during not completed primary course, CTD, glucocorticoids. These findings suggest among are vaccinated but prior infections favorable. Acknowledgements There no specific funding data collection. analysis funded by Alliance. registries supported American College European Associations views expressed here authors. thank our colleagues entered include Ms J Heslett, Dr S Bourke, E Chan, Jordan, K Lindsay, R Murdoch Stebbings, Disclosure Interests Jonathon Brooks: None declared, Anna Montgomery: Nicola Dalbeth Consultant of: Personal fees AstraZeneca, Dyve Biosciences, Horizon, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs, Hikma, outside abstract, Mark Sapsford: Amy Cooper: Rachel Ngan Kee: Vicki Quincey: Jean Liew Grant/research support from: Pfizer, Suleman Bhana Shareholder Owns restricted stock units Pfizer as employee, Honoraria AbbVie, Novartis, has travel Employee Inc, Monique Gore-Massy Patient consultant Aurinia Pharmaceuticals, Boehringer Ingelheim, Johnson & Johnson, Bristol-Myers Squibb, unrelated abstract. Receives honoraria Jonathan Hausmann Consulting Sobi Biogen, manuscript, Pedro Machado Speakers bureau: PMM consulting/speaker’s Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Orphazyme, Roche UCB, Paul Sufka: Emily Sirotich: Philip Robinson PR reports personal Atom Gilead, GlaxoSmithKline, Kukdong, Roche, Pfizer;, Meeting attendance UCB grant Pharma., Zachary Wallace Zenas Biopharma, Sanofi, Shionogi, Viela Bio, MedPace, abstract., Research Squibb Principia/Sanofi, Jinoos Yazdany Astra Zeneca, Aurinia, Grants BMS Foundation, Rebecca Grainger RG Cornerstones, Novartis; meeting Pfizer.